Thromboelastography With Platelet Mapping to Guide Antiplatelet Therapy After Lower Extremity Revascularization
Key facts
- Where
- Boston, United StatesSee the site
Where in United States
- Massachusetts General HospitalBoston, United StatesNo longer taking part
Trial details
- Who runs it
- Massachusetts General Hospital
- Trial code
- NCT07597239
- Record updated
- 5 November 2026
- Original description
The goal of this clinical trial is to learn if a blood clotting test called thromboelastography with platelet mapping (TEG-PM) can guide blood-thinning medication decisions in adults more than 60 years and older with peripheral artery disease (PAD) who have undergone infrainguinal endovascular surgery. The main questions it aims to answer are:Read full original descriptionShow less
The Use of Thromboelastography With Platelet Mapping to Guide Thromboprophylaxis Following Lower Extremity Revascularization for Peripheral Artery Disease
The goal of this clinical trial is to learn if a blood clotting test called thromboelastography with platelet mapping (TEG-PM) can guide blood-thinning medication decisions in adults more than 60 years and older with peripheral artery disease (PAD) who have undergone infrainguinal endovascular surgery. The main questions it aims to answer are:
* Does TEG-PM-guided antiplatelet therapy lower the rate of thrombosis or clinically significant stenosis of the treated artery within 12 months compared with a historical standard-of-care cohort? * How does TEG-PM-guided therapy affect major amputation, amputation-free survival, mortality, and bleeding?
Participants will:
* Have blood samples taken before the procedure and at 1, 3, and 6 months afterward * Have antiplatelet medications (aspirin, clopidogrel, and/or ticagrelor) escalated or de-escalated based on TEG-PM results through 6 months * Have one additional blood test to check clopidogrel response if taking clopidogrel * Be followed for clinical outcomes through 12 months
Inclusion: Patients requiring infrainguinal endovascular revascularization for peripheral atherosclerosis; Patients of age 60 or older.
Exclusion: Contraindication to standard antiplatelet therapy; Did not undergo an eligible infrainguinal endovascular intervention (e.g., no treatable atherosclerotic lesion, unsuitable anatomy, diagnostic angiography only, or alternative treatment selected); Hybrid procedures involving a substantial open infrainguinal revascularization component (femoral cutdown with infrainguinal endovascular treatment is permitted); Pregnancy or breastfeeding; Inability to undergo serial venous blood sampling; Inability to provide informed consent; Non-atherosclerotic pathology identified as primary etiology.